Cover Image
市場調查報告書

Nuevolution A/S:產品平台分析

Nuevolution A/S - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321358
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Nuevolution A/S:產品平台分析 Nuevolution A/S - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 26 Pages
簡介

Nuevolution A/S是小分子的藥物研發公司。該公司著重於發炎和腫瘤學等治療領域。正與Duke University、Howard Hughes Medical Institute及Lexicon Pharmaceuticals, Inc.進行共同研究。

本報告提供Nuevolution A/S調查分析,提供您企業概要,研究·開發概要,開發平台分析,開發中產品的概要,藥物簡介,最新趨勢和計劃等相關的系統性資訊。

目錄

Nuevolution A/S的概述

  • Nuevolution A/S概要
  • 主要資訊
  • 企業資料

Nuevolution A/S:研究·開發概要

  • 主要的治療領域

Nuevolution A/S:開發平台分析

  • 各開發階段的開發中產品
  • 開發中產品:單獨療法
  • 開發中產品:合作夥伴產品
  • 開發中產品:轉出授權產品

Nuevolution A/S:開發中產品的概要

  • 初期階段的開發中產品

Nuevolution A/S:藥物簡介

  • Small Molecules for Cancer
  • Small Molecules for Inflammation
  • Small Molecules for Undisclosed Indication
  • Small Molecules to Modulate GPCR for Undisclosed Indication

Nuevolution A/S:開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Nuevolution A/S:開發平台的最新趨勢

Nuevolution A/S:暫停中的計劃

Nuevolution A/S:所在地

  • 總公司

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07726CDB

Summary

Global Markets Direct's, 'Nuevolution A/S - Product Pipeline Review - 2015', provides an overview of the Nuevolution A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nuevolution A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Nuevolution A/S including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Nuevolution A/S's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Nuevolution A/S's pipeline products

Reasons to buy

  • Evaluate Nuevolution A/S's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Nuevolution A/S in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Nuevolution A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Nuevolution A/S and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nuevolution A/S
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Nuevolution A/S and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Nuevolution A/S Snapshot
    • Nuevolution A/S Overview
    • Key Information
    • Key Facts
  • Nuevolution A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Nuevolution A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Nuevolution A/S - Pipeline Products Glance
    • Nuevolution A/S - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Nuevolution A/S - Drug Profiles
    • Small Molecules for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Modulate GPCR for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nuevolution A/S - Pipeline Analysis
    • Nuevolution A/S - Pipeline Products by Target
    • Nuevolution A/S - Pipeline Products by Molecule Type
    • Nuevolution A/S - Pipeline Products by Mechanism of Action
  • Nuevolution A/S - Recent Pipeline Updates
  • Nuevolution A/S - Dormant Projects
  • Nuevolution A/S - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Nuevolution A/S, Key Information
  • Nuevolution A/S, Key Facts
  • Nuevolution A/S - Pipeline by Indication, 2015
  • Nuevolution A/S - Pipeline by Stage of Development, 2015
  • Nuevolution A/S - Monotherapy Products in Pipeline, 2015
  • Nuevolution A/S - Partnered Products in Pipeline, 2015
  • Nuevolution A/S - Partnered Products/ Combination Treatment Modalities, 2015
  • Nuevolution A/S - Out-Licensed Products in Pipeline, 2015
  • Nuevolution A/S - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Nuevolution A/S - Discovery, 2015
  • Nuevolution A/S - Pipeline by Target, 2015
  • Nuevolution A/S - Pipeline by Molecule Type, 2015
  • Nuevolution A/S - Pipeline Products by Mechanism of Action, 2015
  • Nuevolution A/S - Recent Pipeline Updates, 2015
  • Nuevolution A/S - Dormant Developmental Projects,2015

List of Figures

  • Nuevolution A/S - Pipeline by Top 10 Indication, 2015
Back to Top